Skip to main content

Table 2 Likelihood of receiving a prolactin test: proportional hazards regression results

From: Potential bias in testing for hyperprolactinemia and pituitary tumors in risperidone-treated patients: a claims-based study

 

Hazard ratio

95% CI

p Value

Antipsychotic categories vs other typicals (excluded category):

   

Risperidone (yes = 1)

1.341

1.085 to 1.658

0.0067

Clozapine (yes = 1)

0.748

0.411 to 1.362

0.3418

Olanzapine (yes = 1)

0.948

0.788 to 1.229

0.8894

Quetiapine (yes = 1)

0.927

0.738 to 1.164

0.5124

Ziprasidone (yes = 1)

1.162

0.857 to 1.576

0.3343

Haloperidol (yes = 1)

0.852

0.609 to 1.319

0.3523

Perphenazine (yes = 1)

0.741

0.416 to 1.319

0.3077

Prolactin-related symptoms prior to event or censoring (yes = 1)*

6.736

5.080 to 8.932

< 0.0001

Interaction of antipsychotic and PPAE:

   

Risperidone × PPAEs

1.406

1.040 to 1.901

0.0269

Clozapine × PPAEs

1.340

0.617 to 2.911

0.4594

Olanzapine × PPAEs

1.156

0.838 to 1.593

0.3771

Quetiapine × PPAEs

0.936

0.673 to 1.302

0.6929

Ziprasidone × PPAEs

1.068

0.686 to 1.663

0.7710

Haloperidol × PPAEs

1.094

0.676 to 1.770

0.7134

Perphenazine × PPAEs

1.608

0.747 to 3.463

0.3077

Age

0.962

0.959 to 0.964

< 0.0001

Male gender

0.329

0.300 to 0.361

< 0.0001

Used another antipsychotic within 6 months prior to treatment (yes = 1)

1.070

0.984 to 1.164

0.1130

Concurrent use of other atypical antipsychotic, ratio of days supply to index antipsychotic days supply

1.647

1.465 to 1.852

< 0.0001

Concurrent use of other typical antipsychotic, ratio of days supply to index antipsychotic days supply

1.136

0.954 to 1.354

0.1531

Diagnosis:

   

Schizophrenia (yes = 1)

1.009

0.925 to 1.101

0.8352

Affective psychosis (yes = 1)

1.318

1.212 to 1.434

< 0.0001

Other psychosis (yes = 1)

0.953

0.879 to 1.032

0.2370

Other non-psychotic mental disorder (yes = 1)

1.266

1.143 to 1.402

< 0.0001

Health coverage vs fee-for-service (excluded category):

   

Medicaid (yes = 1)

0.924

0.830 to 1.028

0.1474

HMO (yes = 1)

1.146

1.016 to 1.293

0.0266

  1. Number of observations with event: 2,796; number of observations censored: 195,130.
  2. *Gynecomastia, galactorrhea, oligomenorrhea, amenorrhea, dysmenorrhea, hypogonadism, hypothyroidism, infertility-male-hypospermatogenesis, infertility-female-pituitary/hypothalamic, impotence-organic, psychosexual dysfunction, genitourinary malfunctions arising from mental factors, and alopecia.
  3. CI, confidence interval; HMO, health maintenance organization; PPAEs, potentially prolactin-related adverse events.